Medtronic plc, the global leader in medical technology, announced it will present new data on its MiniMed™ 780G system at the upcoming European Association for the Study of Diabetes (EASD) 60th Annual Meeting in Madrid on September 9-13. The new clinical evidence on the MiniMed™ 780G system will include areas where the company intends to work with global regulators towards expanding access to its diabetes technology including a lower age for those with type 1 diabetes, and type 2 diabetes..

全球医疗技术领导者美敦力公司宣布，将于9月9日至13日在马德里举行的欧洲糖尿病研究协会（EASD）第60届年会上展示其MiniMed™780G系统的新数据。MiniMed™780G系统的新临床证据将包括该公司打算与全球监管机构合作的领域，以扩大其糖尿病技术的使用范围，包括降低1型糖尿病和2型糖尿病患者的年龄。。

Today the MiniMed 780G™ system is approved for use in individuals aged 7 years and above with type 1 diabetes. Maintaining stable blood glucose levels is critical for the physical and cognitive development of very young children. By automating insulin delivery, the burden of diabetes on family life, especially during the night, can also be improved..

如今，MiniMed 780G™系统已被批准用于7岁及以上的1型糖尿病患者。维持稳定的血糖水平对于幼儿的身体和认知发育至关重要。通过自动化胰岛素输送，糖尿病对家庭生活的负担，特别是在夜间，也可以得到改善。。

For women with type 1 diabetes, the challenges to achieving the necessary level of glycemic control in pregnancy to avoid risks to both the mother and the baby extend to delivery and the post-partum period. Pregnant women with type 1 diabetes are advised to aim for tighter control of their glucose levels, typically targeting a range of 63-140 mg/dL (3.5-7.8 mmol/L)1-3, to minimize the risk of high blood sugar levels, which can have adverse effects on the baby's development..

对于患有1型糖尿病的女性来说，在怀孕期间达到必要的血糖控制水平以避免对母亲和婴儿造成风险的挑战延伸到分娩和产后。建议患有1型糖尿病的孕妇更严格地控制血糖水平，通常针对63-140 mg/dL（3.5-7.8 mmol/L）1-3的范围，以最大程度地降低高血糖水平的风险，这可能会对婴儿的发育产生不利影响。。

Data will also highlight the ability of the system to reduce burden at mealtimes for people living with diabetes and more real-world evidence demonstrating the ability of the MiniMed 780G™ system to help users achieve their glycemic goals.

数据还将突出显示该系统减轻糖尿病患者进餐时负担的能力，以及更多真实世界的证据表明MiniMed 780G™系统能够帮助用户实现血糖目标。

SCIENTIFIC DATA

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.

以下海报和口头科学数据展示代表了美敦力员工和独立调查人员在研究中使用美敦力设备的工作。

“The LENNY randomized crossover trial demonstrates the MiniMed™ 780G system is safe and effective for children aged 2-6” –oral presentation (LBA OP O2) by Prof. Tadej Battelino, MD, Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Slovenia on Friday, September 13 at 12:15 CEST (Venue: Cairo Hall) .

“LENNY随机交叉试验证明MiniMed™780G系统对2-6岁儿童安全有效”-由斯洛文尼亚卢布尔雅那大学儿科和青少年内分泌系主任Tadej Battelino教授于9月13日星期五12:15在CEST（地点：开罗大厅）进行的口头介绍（LBA OP O2）。。

“Glycemic control is not affected by season in MiniMed™ 780G system users – a real-world study from Italy” – short oral discussion (850) by Emanuele Bosi, Head physician of the General Medicine, Diabetes and Endocrinology Department and Director of the Diabetes Research Institute at Ospedale San Raffaele, Italy on Wednesday, September 11 at 12:45 CEST (Venue: Station 13) .

“MiniMed™780G系统用户的血糖控制不受季节影响-来自意大利的一项现实研究”-意大利圣拉斐尔奥斯佩代尔糖尿病与内分泌科主任医师、糖尿病研究所所长Emanuele Bosi于9月11日星期三12:45（CEST地点：13号站）进行简短的口头讨论（850）。。

“GLP-1 receptor agonist effects in people with type 2 diabetes using MiniMed™ advanced hybrid closed-loop therapy” – short oral discussion (775) by John Shin, Ph.D., MBA, Senior Clinical Research Director, Medtronic Diabetes on Thursday, September 12 at 12:45 CEST (Venue: Station 11)

“使用MiniMed™高级混合闭环疗法对2型糖尿病患者的GLP-1受体激动剂作用”-美敦力糖尿病高级临床研究总监John Shin博士于9月12日星期四12:45在CEST（地点：11号站）进行简短的口头讨论（775）

“Postprandial insulin strategy for improving glycemic control after a missed meal bolus in persons with type 1 Diabetes users of the Advanced Hybrid Closed Loop (AHCL) Minimed 780G™ system.” – short oral discussion (781) by Prof. Bruno Grassi MD, Nutrition, Diabetes and Metabolism unit, Pontificia Universidad Católica de Chile on Thursday, September 12 at 14:00 CEST (Venue: Station 11) .

“高级混合闭环（AHCL）最小780G™系统的1型糖尿病患者在错过餐后推注后改善血糖控制的餐后胰岛素策略。”——智利天主教大学营养、糖尿病和代谢科Bruno Grassi博士于9月12日星期四14:00在CEST（地点：11号站）进行的简短口头讨论（781）。。

“Real-world performance of the Minimed™ 780G safe meal bolus feature” – short oral discussion (782) by Venkataramana Putcha, Principal AI Data Science Engineer, Medtronic Diabetes on Thursday, September 12 at 14:00 CEST (Venue: Station 11)

美敦力糖尿病首席人工智能数据科学工程师Venkataramana Putcha于9月12日星期四CEST 14:00（地点：11号站）进行了“Minimed™780G安全餐丸功能的真实表现”-简短的口头讨论（782）

“Advanced hybrid closed loop compared to standard insulin therapy in type 1 diabetes during delivery and early postpartum” - short oral discussion (820) by Kaat Beunen, PhD scientist at KU Leuven, on Thursday, September 12 at 12:45 CEST (Venue: Station 12)

9月12日星期四12:45 CEST（地点：12号站），鲁汶大学博士科学家Kaat Beunen进行了简短的口头讨论（820），“在分娩和产后早期，与标准胰岛素治疗相比，先进的混合闭环治疗1型糖尿病”

“Cardiopulmonary and aerobic exercise tests assessing multiple biomarkers and hormones in type 1 diabetes under different circumstances: the act-one study” –oral presentation (LBA OP O2) by Francesca De Ridder, PhD scientist at University of Antwerp, on Tuesday, September 10 at 15:45 CEST (Venue: Cairo Hall).

“在不同情况下评估1型糖尿病多种生物标志物和激素的心肺和有氧运动测试：act one研究”-安特卫普大学博士科学家Francesca De Ridder于9月10日星期二15:45 CEST（地点：开罗大厅）进行的口头报告（LBA OP O2）。

MEDTRONIC SPONSORED EVENTS

Medtronic Symposium: “Expanding Horizons in Insulin Therapy: Applications of MiniMed™ 780G system. Monday, September 9, from 13:30-15:00 CET (06:30-08:00 CT) (Venue: Sydney Hall and online), chaired by Prof. Dídac Mauricio, MD PhD, Director of the Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau CIBERDEM, Spain and Prof.

美敦力研讨会：“扩大胰岛素治疗的视野：MiniMed™780G系统的应用。9月9日星期一，CET时间13:30-15:00（CT时间06:30-08:00）（地点：悉尼大厅和在线），由Dídac Mauricio教授，医学博士，西班牙圣克鲁医院内分泌与营养系主任和教授主持。

Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes..

医学博士Ohad Cohen，美敦力糖尿病公司高级全球医疗事务总监。。

Expert

专家

Topic

主题

Prof. Ohad Cohen (Switzerland)

奥哈德·科恩教授（瑞士）

MD

医学博士

Meeting the needs of diverse populations

满足不同人群的需求

Prof. Tadej Battelino (Slovenia)

Tadej Battelino教授（斯洛文尼亚）

MD, PhD

The MiniMed™ 780G System study in very young children with type 1 diabetes – First results from the LENNY study

MiniMed™780G系统在非常年幼的1型糖尿病儿童中的研究-莱尼研究的首次结果

Prof. Tali Cukierman-Yaffe (Israel)

Tali Cukierman Yaffe教授（以色列）

MD, PhD

医学博士、博士

Using MiniMed™ 780G system in Pregestational Type 1 Diabetes

MiniMed™780G系统在妊娠前1型糖尿病中的应用

Dr. Pablo Mora (US)

Pablo Mora博士（美国）

MD

医学博士

The MiniMed 780G system performance in people living with type 2 diabetes requiring insulin treatment

需要胰岛素治疗的2型糖尿病患者的最小780G系统性能

“Addressing the needs of all people living with type 1 diabetes”, chaired by Dr. Martín Cuesta, Hospital Clínico San Carlos, Madrid, Spain and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes with speakers on Thursday, September 12 from 12:15-12:45 CET (05:15-05:45 CT) .

“满足所有1型糖尿病患者的需求”，由西班牙马德里圣卡洛斯Clínico医院的Martín Cuesta博士和美敦力糖尿病公司全球医学事务高级主任Ohad Cohen教授主持，于9月12日星期四，CET 12:15-12:45（CT 05:15-05:45）。。

Exhibit Booth featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for healthcare professionals and patients. In-Booth Presentations will include:

展台以互动组件为特色，重点关注糖尿病技术、临床结果以及为医疗保健专业人员和患者提供的支持。展台内演示将包括：

“New generation of Smart MDI therapy,” on Tuesday, September 10 at 10:30 CEST and Wednesday, September 11 at 10:30 CEST by Madison Smith, Ph.D., R.N., CDCES, R&D Senior Clinical Product Manager, Medtronic Diabetes

“新一代智能MDI疗法”，于9月10日星期二10:30 CEST和9月11日星期三10:30 CEST由麦迪逊·史密斯博士，R.N.，CDCES，美敦力糖尿病研发高级临床产品经理

* The MiniMed™ 780G system has not been approved for use for children aged 2-6 years, pregnancy, or type 2 diabetes by the FDA or other regulatory bodies.

*MiniMed™780G系统尚未被FDA或其他监管机构批准用于2-6岁儿童，怀孕或2型糖尿病。

1 Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593–603.

。糖尿病护理2019；42:1593年至603年。

2 Benhalima K, Beunen K, Siegelaar SE, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol 2023; 11: 490–508.

2 Benhalima K，Beunen K，Siegelaar SE等。妊娠期1型糖尿病的管理：生活方式，药物治疗和实现血糖目标的新技术的更新。柳叶刀糖尿病内分泌2023；11： 490-508。

3 ElSayed NA, Aleppo G, Aroda VR, et al. 15. Management of diabetes in pregnancy: standards of care in diabetes—2023. Diabetes Care 2023; 46 (suppl 1): S254–66.

3 ElSayed NA，Aleppo G，Aroda VR等15。妊娠期糖尿病的管理：2023年糖尿病护理标准。糖尿病护理2023；46（补充1）：S254-66。

About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)

关于美敦力的糖尿病业务（www.medtronicdemabetes.com）

Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront..

美敦力糖尿病公司（Medtronic Diabetes）的使命是通过最先进的糖尿病技术，使个人能够按照自己的条件生活，并在需要时以何种方式随时提供支持，从而减轻糖尿病的负担。40多年来，我们开创了同类创新的先河，致力于通过下一代传感器（CGM）、智能剂量系统以及数据科学和人工智能的力量来设计糖尿病管理的未来，同时始终将客户体验放在最前沿。。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。。我们是美敦力。总部位于爱尔兰戈尔韦的美敦力公司是全球领先的医疗保健技术公司，通过寻找和寻找解决方案，大胆应对人类面临的最具挑战性的健康问题。我们的使命是减轻痛苦，恢复健康，延长寿命，我们团结了150多个国家的95000多名充满激情的全球团队。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永不满足的好奇心以及帮助所有需要帮助的人的愿望，我们提供了创新技术，每秒钟、每小时、每天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn..

随着我们增强洞察力驱动的护理、以人为本的体验以及为我们的世界带来更好的结果，对我们的期望会更高。在我们所做的每件事中，我们都在创造非凡。有关美敦力（纽约证券交易所代码：MDT）的更多信息，请访问www.Medtronic.com，并在LinkedIn上关注美敦力。。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性声明都会受到风险和不确定性的影响，例如美敦力向美国证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果存在重大差异。

For more information, contact:

有关更多信息，请联系：

Ashley Patterson

阿什利·帕特森

Global Communications

全球通信

+1-818-576-3025

+1-818-576-3025

Ryan Weispfenning

瑞安·韦斯芬宁

Investor Relations

投资者关系

+1-763-505-4626

+1-763-505-4626